|Bid||77.68 x 800|
|Ask||77.72 x 800|
|Day's Range||76.23 - 77.93|
|52 Week Range||47.75 - 78.82|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating the investigational Lenti-D gene therapy for the treatment of cerebral adrenoleukodystrophy (or CALD) in boys aged 17 years or less. The Phase 2/3 Starbeam study met its enrollment goal with the data reported by Bluebird Bio as of April 25. Thirty-one patients were studied, and 29 of them received Lenti-D gene therapy.
In the second quarter, Alkermes (ALKS) reported revenues of $304.6 million—compared to $218.8 million in the second quarter of 2017, which reflects ~39% growth year-over-year. In the second quarter, Alkermes generated revenues of $128.2 million as manufacturing and royalty revenues. Alkermes reported revenues of $109.8 from product sales in the second quarter—compared to $88.7 million in the second quarter of 2017.
Shares of Bayer (BAYRY) crash as its newly acquired company Monsanto was fined $289 million over allegations that its weedkiller caused cancer.
Spectrum (SPPI) reports wider-than-expected loss in the second quarter and misses on revenues. Rolontis successful in second phase III study.
Nektar's (NKTR) second-quarter earnings meet estimates. Although revenues soar on one-time payment from Bristol-Myers, product sales fall. Shares down.
Sarepta's (SRPT) loss per share is narrower than the Zacks Consensus Estimate while sales also beat the same. Exondys 51 continues its strong performance.
The FDA accepts Catalyst's (CPRX) NDA for its lead pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and an action date of Nov 28, 2018 is set for the same.
Arena Pharmaceuticals (ARNA) misses second-quarter earnings estimates. Its three key pipeline candidates, ralinepag, etrasimod and Olorinab/APD371, remain in focus.
Neurocrine Biosciences (NBIX) generated revenues of $96.9 million in the second quarter of 2018 compared to $6.3 billion in the second quarter of 2017. In the second quarter of 2018, Neurocrine Biosciences witnessed ~36% growth sequentially. In the first half of 2018, Neurocrine Biosciences generated revenues of $168.0 million.
Ionis Pharmaceuticals (IONS) is one of the leading RNA-targeted therapeutics companies. The company aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes approved products in collaboration with other pharmaceutical companies. Ionis is set to release its Q2 2018 earnings on August 7. Wall Street analysts estimate a net loss of $0.09 per share on revenues of $135.5 million in the second quarter of 2018.
Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates. It reported EPS of -$2.91 on revenue of $7.8 million during Q2 2018, compared with -$2.35 on revenue of $9.6 million. The chart below compares the company’s revenue and EPS since Q1 2017.
Geron (GERN) meets earnings estimates on higher sales in the second quarter. Operating expenses however increase year over year.
Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018, compared to estimates for EPS of $0.34 on revenues of $473.8 million.